O
Orthogon Therapeutics
Meeting a critical need in translational drug discovery by bridging frontier research with formal drug development
About Orthogon Therapeutics
Orthogon Therapeutics is a biopharmaceutical company that specializes in the development of antiviral medicines for challenging drug targets. The company's primary focus is on creating small molecule therapies, with a lead candidate being the first-ever oral treatment for BK polyomavirus, a significant viral complication for transplant recipients.
By leveraging advanced structure-based drug design and biophysics, Orthogon Therapeutics designs and develops its therapies. The company's business model is centered on research and development, with the goal of bringing new antiviral drugs to market. Its target market includes transplant patients and others who are susceptible to opportunistic viral infections. The company generates revenue through financing and partnerships to advance its drug candidates through the development and clinical trial process.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2026 | $11M | $44M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Dec 2024 | $5.2M | $40M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Orthogon Therapeutics is 20 monthly website visits, down 99.1% over the last three months. Orthogon Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Orthogon Therapeutics in the Canton ecosystem
The Orthogon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- OTOtrfoundation
Other known investors1 additional known investor
Startup Leadership Program- SF
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Orthogon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Orthogon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










